Lamotrigine-Induced Gingival Enlargement: An Older Problem Due to a Newer Drug - A Rare Case Report.
Gingival enlargement
gingivectomy
lamotrigine
Journal
Clinical advances in periodontics
ISSN: 2163-0097
Titre abrégé: Clin Adv Periodontics
Pays: United States
ID NLM: 101597440
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
28
05
2020
accepted:
06
08
2020
pubmed:
28
8
2020
medline:
24
6
2022
entrez:
28
8
2020
Statut:
ppublish
Résumé
Gingival enlargement (GE) due to anti-epileptic drugs (AEDs) shows a high prevalence rate. However, lamotrigine, a newer AED, has not shown to induce GE. The present case report describes a rare case of GE in a patient with epilepsy under lamotrigine therapy for the past 3 years. In this report, successful management of lamotrigine-influenced GE in a 24-year-old patient with epilepsy by gingivectomy followed by stringent oral hygiene protocol is presented. The present case report suggests that, even this newer AED can cause GE and the oral hygiene status of the patients could be an important triggering factor.
Substances chimiques
Anticonvulsants
0
Lamotrigine
U3H27498KS
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
130-133Informations de copyright
© 2020 American Academy of Periodontology.
Références
Wester K, Jönsson AK, Spigset O, Druid H, Hägg S. Incidence of fatal adverse drug reactions: a population based study. Br J Clin Pharmacol. 2008;65:573-579.
Ciancio SG. Medications' impact on oral health. J Am Dent Assoc. 2004;135:1440-1448.
Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000 1999;21:176-196.
Suzuki JB, Misch CE. Periodontal and Maintenance Complications. In: Resnik R, Misch CE Misch's Avoiding Complications in Oral Implantology. St. Louis, MO: Mosby Elsevier; 2018;771-826.
Leach MJ, Lees G, Riddall DR. Lamotrigine: mechanism of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th ed. New York: Raven Press; 1995;861-869.
Garnett WR. Lamotrigine: pharmacokinetics. J Child Neurol. 1997;12:S10-S15.
Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Curr Drug Saf 1998;18:281-296.
Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018-1025.
Ghaffarpour M, Hejazie SS, Harirchian MH, Pourmahmoodian H. Phenytoin, carbamazepine, sodium valproate induced cutaneus reactions. Acta Medica Iranica 2005;43:37-42.
Bokenkamp A, Bonhorst B, Beier C, et al. Nifedipine aggravates cyclosporine A-induced hyperplasia. Pediatr Nephrol 1994;8:181-185.
Greene JG, Vermillion JR. The simplified oral hygiene index. J Am Dent Assoc. 1964;68:7-13.
Newman MG, Takei H, Klokkevold PR, Carranza FA. Carranza's Clinical Periodontology. 11th ed. St. Louis, MO: Elsevier Saunders; 2011;834-836.
Brown RS, Arany PR. Mechanism of drug-induced gingival overgrowth revisited: a unifying hypothesis. Oral dis. 2015;21:51-61.
Baden E. Sodium dilantin gingival hyperplasia and conservative treatment: a case report. J Dent Med 1950;5:46-52.
Ciancio SG. Medications: a risk factor for periodontal disease diagnosis and treatment. J Periodontol. 2005;76:2061-2065.
Nuki K, Cooper SH. The role of inflammation in the pathogenesis of gingival enlargement during the administration of diphenyl hydantoin sodium in cats. J Periodontal Res 1972;7:102-110.